

AMENDMENTS TO THE CLAIMS

This listing of claims provided below will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A method of determining the presence or amount of newly synthesized antibodies contained within lymphocytes comprising:

obtaining a sample containing lymphocytes from an animal;
disrupting the lymphocytes to release the antibodies or parts thereof; and
determining the presence or amount of the antibodies or parts thereof in the sample

2. (Currently Amended) The method of claim 1, wherein the sample is ~~lymphatic fluid~~ lymph or blood.

3. (Previously Presented) The method of claim 1, wherein the lymphocytes are disrupted by physical disruption or by contacting the lymphocytes with a cell-disrupting buffer or solution.

4. (Previously Presented) The method of claim 1, wherein the presence or amount of the released antibodies or parts thereof are determined by binding the released antibodies or parts thereof to one or more antigens which recognize the released antibodies or parts thereof.

5. (Previously Presented) The method of claim 1, wherein the presence or amount of the released antibodies or parts thereof are detected by a solid phase binding assay.

6. (Previously Presented) The method of claim 5, wherein the solid phase binding assay uses a solid support comprising one or more solid phase antigens that are recognized by the antibodies or parts thereof.

7. (Previously Presented) The method of claim 5, wherein the solid phase binding assay uses a solid support comprising one or more solid phase antibodies which recognize the antibodies or parts thereof.

8. (Previously Presented) The method of claim 1, wherein the sample is neonate or infant blood and the method is used to detect antibodies or parts thereof synthesized by the animal.

9. (Currently Amended) The method of claim 1, further comprising storing the sample at a temperature of ~~about 40°C~~ about 4 °C before the lymphocytes are disrupted, or after the lymphocytes are disrupted but prior to determining the presence or amount of the antibodies or parts thereof.

10. (Previously Presented) The method of claim 2, wherein the sample has a volume of less than 1 ml.

11. (Previously Presented) The method of claim 1, further comprising isolating the lymphocytes from the sample before they are disrupted.

12. (Previously Presented) The method of claim 1, wherein determining the presence or amount of antibodies or parts thereof is performed by immunoassay.

13. (Previously Presented) The method of claim 12, wherein the immunoassay is ELISA.

14. (Previously Presented) The method of claim 1, wherein the presence or amount of the antibodies is determined by contacting the antibodies or

parts thereof with a compound to produce a product that yields a spectrophotometrically detectable signal.

15. (Previously Presented) The method of claim 4, further comprising testing the sample of disrupted lymphocytes with one or more negative control antigens.

16. (Previously Presented) The method of claim 5, wherein the solid phase binding assay uses more than one solid phase and each solid phase is used to determine the presence or amount of different antigens or parts thereof.

17. (Withdrawn Without Prejudice).

18. (Withdrawn Without Prejudice).

19. (Withdrawn Without Prejudice).

20. (Previously Presented) A method of determining the presence or amount of infection indicators in a sample, said infection indicators formed in response to an immunogen, comprising:

- obtaining a sample containing lymphocytes;
- disrupting the lymphocytes to release the infection indicators; and
- detecting the released infection indicators to determine the presence or amount of 10 infection indicators in the sample.

Please add the following new claims:

--21. (New) A method of determining the presence or amount of newly synthesized antibody in a body fluid sample or a sample derived from lymph nodes, nodules, or glands in response to an immunogen comprising:

- detecting the released antibodies or parts thereof in a sample containing

lymphocytes which have been disrupted, whereby to release the synthesized antibodies or parts thereof associated with said lymphocytes, whereby to determine the presence or amount of newly synthesized antibody in said sample.

22. (New) The method as claimed in claim 21 comprising the steps of:
(i) obtaining the sample containing lymphocytes;
(ii) disrupting said lymphocytes whereby to release antibodies or parts thereof associated with said lymphocytes; and
(iii) detecting the released antibodies or parts thereof, whereby to determine the presence or amount of newly synthesized antibody in said sample.

23. (New) The method as claimed in claim 21 or 22, wherein said sample is lymph or blood.

24. (New) The method of claim 23, wherein said sample is lymph or peripheral blood.

25. (New) The method as claimed in claim 21 or 22, wherein the sample is not incubated to promote synthesis or secretion of antibodies prior to the method.

26. (New) The method as claimed in claim 21 or 22, wherein the lymphocytes are disrupted by using physical disruption means or cell-disrupting buffers or solutions.

27. (New) The method as claimed in claim 21 or 22, wherein said antibodies or parts thereof are detected by binding to one or more antigens which recognize said antibodies or parts thereof.

28. (New) The method as claimed in claim 21 or 22, wherein the released

antibodies are detected by means of a solid phase binding assay.

29. (New) The method of claim 28, wherein said solid phase carries one or more antigens recognized by the antibody or antibodies or parts thereof to be detected.

30. (New) The method of claim 29, wherein the antibodies are target antibodies.

31. (New) The method of 29, wherein said solid phase carries one or more antibodies, which recognize the target antibody or target antibodies or parts thereof to be detected.

32. (New) The method as claimed in claim 21 or 22, wherein the method is performed on neonate or infant blood samples for distinguishing between newly synthesized antibodies and passively transferred maternal antibodies.

33. (New) The method as claimed in claim 21 or 22, wherein prior to disrupting the lymphocytes, or after disruption but prior to the detection step, said sample is stored at about 4 °C or less.

34. (New) The method of claim 23, wherein said blood sample for use in the method, or for preparing lymphocytes for use in the method, has a volume of less than 1 ml.

35. (New) The method as claimed in claim 21 or 22, wherein lymphocytes directly isolated from said sample are used in the method.

36. (New) The method as claimed in claim 21 or 22, wherein the detecting

step is performed by immunoassay

37. (New) The method of claim 36, wherein the immunoassay is ELISA.

38. (New) The method as claimed in any one of claims 29, 33, or 36, wherein one or more antigens, recognized by the target antibodies immobilized on said solid phase, are contacted with said solid phase.

39. (New) The method as claimed in any one of claims 29, 30, 31, 34, or 37, wherein one or more antibodies, which recognize target antibodies immobilized on said solid phase, are contacted with said solid phase.

40. (New) The method as claimed in claim 21 or 22, wherein a soluble substrate is used for the detection step and yields a spectrophotometrically detectable signal.

41. (New) The method as claimed in claim 21 or 22, wherein a negative control antigen is used.

42. (New) The method as claimed in any one of claims 28, wherein multiple solid phases are employed each bearing a different target antigen.

43. (New) A method of diagnosing or monitoring infection of a human or non-human animal or a part of said animal by an immunogen, wherein said method comprises obtaining a lymphocyte-containing sample from said animal, determining the presence or amount of newly synthesized antibodies or parts thereof associated with said lymphocytes directed to said immunogen according to the method as claimed in claim 21 or 22 and determining the presence or extent of infection by said immunogen by

reference to appropriate control and/or reference samples.

44. (New) The method as claimed in claim 21 or 22, wherein said immunogen is a bacterial or viral antigen and diagnosis or monitoring of infection by the source bacterium or virus is determined.

45. (New) The method of claim 43, wherein said antigen is derived from a virus selected from the list consisting of Herpes Simplex virus, Cytomegalovirus, human immunodeficiency virus (HIV) and any of the Hepatitis viruses as well as Toxoplasma and Epstein-Barr virus (EBV).

46. (New) The method of determining the presence or amount of infection indicators in a sample in response to an immunogen comprising:

obtaining a sample containing lymphocytes; disrupting said lymphocytes whereby to release the infection indicators to be detected; and detecting the released infection indicators whereby to determine the presence or amount of infection indicators in said sample, according to the method as claimed in claim 21 or 22.--